Search

Displaying results 1761 - 1770 of 1901 in total
  1. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.

  2. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.

    Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha Antagonists
  3. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    According to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967].

  4. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  5. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.

  6. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363]

  7. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously

  8. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]

  9. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    [A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this

  10. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    [L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United